SHINE is headquartered in Janesville, Wisconsin. Phoenix, our manufacturing division, operates a manufacturing facility and industrial imaging center in Fitchburg, Wisconsin. We are expanding rapidly, with new facilities under construction in Janesville and facilities slated for construction in the Netherlands and on the West Coast of the United States.
We are headquartered in Janesville, Wisconsin. For the past several years, our corporate headquarters has been in downtown Janesville. A new headquarters is constructed adjacent to our medical isotope production facility on our 105-acre campus across from the Southern Wisconsin Regional Airport. In 2020, we broke ground on a new global headquarters. The new 35,000-square-foot facility lies directly northeast of our medical isotope production facility on the SHINE campus.
Building One is our state-of-the-art technology development center as well as small-scale therapeutic isotope production facility for Lutetium-177 (Lu-177). Ground was broken on the facility in 2017 with the initial intent to house the first fully integrated, full-size Mo-99 production system for training employees and developing operating history with the equipment. The building continues to be used for that function today, as well as operating as a bridge production facility for Lu-177. We will continue to produce Lu-177 under GMP conditions at Building One while the large-scale facility (Cassiopeia) is under construction.
Mo-99 production facility
Our production facility for neutron-generated isotopes will be the largest dedicated medical isotope production facility in the world. We broke ground on the 43,000-square-foot facility in 2019 and finished building the shell in the first quarter of 2021. In this facility we will be using a patented, proprietary manufacturing process to produce medical isotopes such as molybdenum-99 (Mo-99), an essential component in medical imaging procedures such as SPECT scans. At full capacity, we believe the facility will be capable of satisfying the current patient demand for Mo-99 in the United States or the equivalent of over one-third of the world’s current total demand.
SHINE Therapeutics is focused on addressing the need for therapeutic isotopes used to treat cancer. Such isotopes include Lu-177, which is used in cancer treatment along with a disease-targeting molecule to destroy tumor cells while leaving healthy cells unharmed. At Cassiopeia, SHINE Therapeutics will produce Lu-177 and will branch out into producing other therapeutic isotopes as well. We expect this to be the largest production facility for Lu-177 in the world with a capacity of 300,000 patient doses per year.